Results 121 to 130 of about 8,661 (182)

Viral kinetics in adults with Covid-19 treated with nirmatrelvir-ritonavir or molnupiravir: a population-based, observational cohort study. [PDF]

Virol J
Prager M, Ensle D, Eser H, Glötzl F, Riedl B, Szell M, Valipour A, Zoufaly A, Wenisch C, Haider D, Burgmann H, Thalhammer F, Götzinger F, Jilma B, Karnthaler U, Zeitlinger M, Jorda A.   +16 more
europepmc   +1 more source

Pharmacokinetics, pathology and efficacy of SARS-CoV-2 main protease inhibitor VPC285785 in a murine model of coronavirus infection. [PDF]

Sci Rep
Smith JR, Toro A, Sabater A, Kovacic S, Ban F, Arevalo AP, Crispo M, Gueron G, Young RN, Cherkasov A.   +9 more
europepmc   +1 more source

Nirmatrelvir/Ritonavir-Induced Calcium Channel Blocker Intoxication Successfully Treated by High Dose Insulin Therapy. [PDF]

Acta Cardiol Sin
Chen CY, Cia CT.
europepmc   +1 more source

Medication errors and associated serious outcomes in COVID-19 antivirals: a real-world study based on FDA Adverse Event Reporting System database. [PDF]

Ther Adv Drug Saf
Xiong X, Chen Z, Yan B.
europepmc   +1 more source

Real-world untreated risk of hospitalization and death in a nirmatrelvir/ritonavir treatment-eligible population with mild-to-moderate COVID-19 in the United States: a systematic literature review. [PDF]

BMC Infect Dis
Migliaccio-Walle K, Mugwagwa T, Cha-Silva AS, Gong CL, Campbell D, Quercia R, Bergroth T, Veenstra DL, Moran MM, Dzingina M.   +9 more
europepmc   +1 more source

Effectiveness of nirmatrelvir/ritonavir and molnupiravir in reducing the risk of short-term and long-term cardiovascular complications of COVID-19: a target trial emulation study. [PDF]

Nat Commun
Guo Z, Wei Y, Lin G, Jia KM, Boyer C, Wang H, Li C, Hung CT, Yam CHK, Chow TY, Zhao S, Li K, Yang A, Mok CKP, Hui DS, Yeoh EK, Chong KC.   +16 more
europepmc   +1 more source

Eligibility for Nirmatrelvir/Ritonavir Among Adults With an Acute Care COVID-19 Encounter: A Retrospective Cohort Study From Alberta, Canada. [PDF]

Pharmacoepidemiol Drug Saf
Aponte-Hao S, Vu K, Randall JR, Martins KJB, Nguyen PU, Saxinger L, Leal J, Rennert-May E, Rafferty E, Williamson T, Klarenbach SW.   +10 more
europepmc   +1 more source

Insights from integrated covalent docking and molecular dynamics simulations of nirmatrelvir analogs as potential SARS-CoV-2 M^pro inhibitors. [PDF]

Sci Rep
Ibrahim MAA, Khaled DMA, Mahmoud DGM, Abdelrahman AHM, Sidhom PA, Han Y, Shoeib T, Aldahmash B, Rady A.   +8 more
europepmc   +1 more source

Successful Treatment of Multiple Myeloma Complicated With SARS-CoV-2 Infection: A Case Report. [PDF]

Case Rep Med
Meng Y, Duan B, Gao L, Huang W, Wan F.
europepmc   +1 more source

Nirmatrelvir/ritonavir use reduces risk for long COVID in patients with immunodeficiency. [PDF]

J Hum Immun
Gilbert KM, Aglan M, Jogdand A, Khairnar NV, Ssemaganda H, Ong MS, Farmer JR.   +6 more
europepmc   +1 more source